BofA Raises J&J Target but Sees Q3 Earnings 12% Below Street
BofA Securities raised its price target on Johnson & Johnson NYSE:JNJ to $278 from $263 while keeping a Neutral rating, lifting its forecasts for Icotyde and updating its model for recent in-process research and development charges. J&J shares were down 0.22% in premarket.The new target applies 22x…